Fat decellularized biological material and preparation method thereof

By performing multi-step processing of adipose tissue, cells-free adicellular biomaterials were prepared, which solved the problem of the removal of active protein factors in the prior art, achieved high biological activity and long-term repair effects, and was suitable for industrial production .

CN118924955AInactive Publication Date: 2024-11-12SHANGHAI SONDRAY BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310490009.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-04
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art removes cellular substances and viruses from adipose tissue, which will remove active protein factors, resulting in a decrease in the biological activity of adipose decellularized products and affects the ability of tissue repair and regeneration.

Method used

Through a multi-step process, including rinsing, centrifugation, emulsification, filtration, disinfection, decellularization and degreasing, cell-free adipose decellularization biological material is prepared, retaining the active protein factor in the adipose tissue and lyophilized by freeze-drying The formation of porous structures enhances the biological activity and preservation ability of the material.

Benefits of technology

This method retains the active protein factor in adipose tissue, improves the biosafety and repair ability of biological materials, and achieves long-term tissue repair. The freeze-dried material has a porous structure, which is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a fat decellularized biological material. Specifically, the fat decellularized biological material is a cell-free extract derived from adipose tissues, and is a cell-free fat extract solid obtained by decellularizing, degreasing and other processes of a cell-free fat extracting solution in a fat mixture obtained by cleaning, crushing and separating the adipose tissues and the fat mixture. The adipose decellularized biological material prepared through mixing has long-acting tissue repair and tissue regeneration guide capabilities, and can be used in the fields of soft tissue defect repair, plastic filling and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical materials, and in particular to a fat decellularized biomaterial and a preparation method thereof. Background Art

[0002] Autologous tissue transplantation is generally considered the gold standard for tissue repair, but the limited amount of autologous materials and the secondary damage to patients make autologous tissue transplantation have certain limitations. The best scaffold for tissue repair is the extracellular matrix of the target tissue. So far, the commercialized allogeneic extracellular matrix products are mainly dermis, tendon, nerve and bone tissue. Compared with xenogeneic materials, the acquisition of human tissue is very precious and usually comes from cadaver donation programs.

[0003] During liposuction surgery, a large amount of adipose tissue is often discarded as medical waste. Studies have shown that adipose decellularized matrix extracted from fat is used for in vitro adipose tissue engineering and in vivo adipose tissue regeneration, and is not limited to adipose tissue engineering. It also has potential applications in healing wounds, regenerating bones, supporting breast tissue reconstruction, and promoting nerve repair.

[0004] Although much progress has been made in this field, there are still many problems that need to be solved and studied in depth.

[0005] Commercial decellularized products have very high requirements for virus inactivation and immunogenicity elimination. However, the current process of removing cellular material and fat from adipose tissue, and removing viruses and other immunogenic substances, is a complex process that removes active protein factors while decellularizing, greatly reducing the inherent biological activity of the adipose decellularized product, thereby affecting the material's ability to guide tissue repair and regeneration.

[0006] Therefore, it is necessary to provide a new fat decellularized biomaterial and a preparation method thereof to address the deficiencies of the prior art. Summary of the invention

[0007] The purpose of the present invention is to provide a fat decellularized biomaterial and a preparation method thereof, in particular to provide a biomaterial with the ability to repair tissue and guide tissue regeneration and a preparation method thereof, which can be used in the fields of soft tissue defect repair, plastic surgery and filling.

[0008] In a first aspect of the present invention, a fat decellularized biomaterial is provided, wherein the fat decellularized biomaterial is prepared by the following method, which comprises the following steps:

[0009] (1) providing a fat tissue raw material, crushing the fat tissue raw material, and rinsing the fat tissue raw material to obtain rinsed fat tissue;

[0010] (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer;

[0011] (3) emulsifying the intermediate layer to obtain an emulsified fat mixture;

[0012] (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B;

[0013] (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract C;

[0014] (6) sequentially subjecting the primary fat extract B to emulsification, disinfection, decellularization and defatting treatments to obtain acellular fat extract D;

[0015] (7) The cell-free fat extract C is mixed with D, and post-processed to obtain the adipose decellularized biomaterial.

[0016] In another preferred embodiment, the post-processed adipose decellularized biological material is a solid material.

[0017] In another preferred embodiment, the post-processed adipose decellularized biomaterial is a block material.

[0018] In another preferred embodiment, the adipose decellularized biomaterial is a porous material.

[0019] In another preferred embodiment, the pore size of the adipose decellularized biomaterial is 1-1000 μm.

[0020] In another preferred embodiment, the adipose decellularized biological material contains no cells and no fat droplets.

[0021] In another preferred embodiment, the lipid droplets are oil droplets released after the adipocytes are broken.

[0022] In another preferred embodiment, the “free of fat droplets” means that in the adipose decellularized biological material, the volume of oil droplets accounts for less than 1% of the total liquid, preferably less than 0.5%, and more preferably less than 0.1%.

[0023] In another preferred embodiment, the cells are selected from the group consisting of endothelial cells, adipose stem cells, macrophages, and stromal cells.

[0024] In another preferred embodiment, the “containing no cells” means that the average number of cells in 1 ml of adipose decellularized biological material is ≤1, preferably ≤0.5, more preferably ≤0.1, or 0.

[0025] In another preferred embodiment, in the step (1), physiological saline is used for rinsing.

[0026] In another preferred embodiment, in the step (2), the centrifugation is performed at 800-2500 g, preferably 800-2000 g, more preferably 1000-1500 g, and most preferably 1100-1300 g.

[0027] In another preferred embodiment, in the step (2), the centrifugation time is 1-15 min, preferably 1-10 min, more preferably 1-8 min, and most preferably 1-5 min.

[0028] In another preferred embodiment, in the step (2), the intermediate layer is a fat layer containing fat cells.

[0029] In another preferred embodiment, in the step (2), the layered mixture is divided into three layers, the upper layer is an oil layer, the middle layer is a fat layer containing fat cells, and the lower layer is a water layer.

[0030] In another preferred embodiment, in the step (3), the emulsification is mechanical emulsification.

[0031] In another preferred embodiment, the mechanical emulsification is performed by repeatedly blowing with a syringe (such as blowing 20-200 times, preferably 20-150 times, more preferably 20-100 times, and more preferably 30-50 times).

[0032] In another preferred embodiment, the blowing method is to connect two 10 ml injection syringes to a three-way tube and push and beat repeatedly at a uniform speed.

[0033] In another preferred embodiment, in the step (3), the emulsification includes breaking and emulsifying by a tissue homogenizer.

[0034] In another preferred embodiment, in the step (4), before subjecting the emulsified fat mixture to centrifugal treatment, the step further includes subjecting the emulsified fat mixture to a freezing and then thawing treatment.

[0035] In another preferred embodiment, after the freezing and thawing treatment, the thawed mixture is used for centrifugation.

[0036] In another preferred embodiment, the freezing temperature is -50°C to -120°C, preferably -60°C to -100°C, and more preferably -70°C to -90°C.

[0037] In another preferred embodiment, the thawing temperature is 20-40°C, preferably 25-40°C, and more preferably 37°C.

[0038] In another preferred embodiment, the number of cycles of freezing and thawing is 1-5 times (preferably 1, 2, 3 or 4 times).

[0039] In another preferred embodiment, in the step (4), after centrifugation, the emulsified fat mixture is stratified into four layers, the first layer is an oil layer, the second layer is a residual fat tissue layer, the third layer is a liquid layer, and the fourth layer is a cell / tissue fragment precipitation layer.

[0040] In another preferred embodiment, the intermediate solid layer in step (4) is the second layer, namely the residual fat tissue layer.

[0041] In another preferred embodiment, the intermediate liquid layer in step (4) is the third layer, namely the liquid layer.

[0042] In another preferred embodiment, in the step (4), the centrifugation is performed at 800-2500 g, preferably 800-2000 g, more preferably 1000-1500 g, and most preferably 1100-1300 g.

[0043] In another preferred embodiment, in the step (4), the centrifugation time is 1-15 min, preferably 1-10 min, more preferably 2-8 min, and most preferably 3-7 min.

[0044] In another preferred embodiment, in the step (4), the first layer, the second layer, the third layer and the fourth layer are arranged in sequence from top to bottom.

[0045] In another preferred embodiment, in the step (4), the intermediate liquid layer is a transparent or substantially transparent layer.

[0046] In another preferred embodiment, in the step (4), the intermediate solid layer is yellow or brown.

[0047] In another preferred embodiment, in the step (5), the filtration removes the fat cells or other living cells that may be mixed in the primary fat extract A.

[0048] In another preferred embodiment, in the step (5), the filtration and sterilization are performed using a filter.

[0049] In another preferred embodiment, the filter is a microporous membrane filter.

[0050] In another preferred embodiment, the pore size of the microporous membrane filter is 0.05-0.8 μm, preferably 0.1-0.5 μm, more preferably 0.1-0.4 μm, more preferably 0.15-0.3 μm, more preferably 0.2-0.25 μm, and most preferably 0.22 μm.

[0051] In another preferred embodiment, in the step (5), the filtration and sterilization include first passing through a first filter that can filter out cells, and then passing through a second filter (such as a 0.22 μm filter) that can filter out pathogens (such as bacteria).

[0052] In another preferred embodiment, the step (5) further comprises packaging the fat extract C to form a packaged mixture.

[0053] In another preferred embodiment, the packaged extract is stored frozen or at low temperature.

[0054] In another preferred embodiment, the packaged extract is frozen and stored at -20°C for use. Preferably, the packaged extract is directly used after being thawed at low temperature (such as -4°C) or room temperature after being frozen, or is stored at low temperature (such as 4°C) for a period of time after being thawed and then used.

[0055] In another preferred embodiment, in the step (6), the emulsification treatment includes mechanical emulsification.

[0056] In another preferred embodiment, in the step (6), the emulsification treatment includes homogenization and emulsification using a homogenizer.

[0057] In another preferred embodiment, the rotation speed of the homogenizer is 5000-15000 r / min, preferably 8000-15000 r / min, such as 10000 r / min, 12000 r / min.

[0058] In another preferred embodiment, in the step (6), the emulsification time is 0.5-15 min, preferably 1-10 min, more preferably 1-8 min, and most preferably 1-5 min.

[0059] In another preferred embodiment, in the step (6), the emulsification treatment further comprises the step of centrifugally separating the oil layer.

[0060] In another preferred embodiment, the centrifugation is performed at 1000-8000 r / min, preferably 2000-5000 r / min, and more preferably 4000 r / min.

[0061] In another preferred embodiment, the centrifugation time is 2-20 min, preferably 5-15 min, more preferably 10 min.

[0062] In another preferred embodiment, in the step (6), the disinfection treatment includes the step of mixing with a disinfectant for disinfection.

[0063] In another preferred embodiment, in the step (6), the disinfection treatment includes mixing with a disinfectant, and discarding the liquid layer after shaking.

[0064] In another preferred embodiment, in the step (6), the sterilization treatment includes irradiation sterilization, and the liquid layer is discarded after the shaking treatment.

[0065] In another preferred embodiment, the disinfectant is a mixed solution of peracetic acid and ethanol, or supercritical carbon dioxide.

[0066] In another preferred embodiment, the concentration of the peracetic acid is 0.05-3%, preferably 0.1-2%, more preferably 0.1-1%, such as 0.5%.

[0067] In another preferred embodiment, the concentration of ethanol is 1-24%, preferably 2-20%, more preferably 2-10%, such as 4%, 5%, 8%.

[0068] In another preferred embodiment, the mass ratio of the solid content obtained after emulsification to the disinfectant is 1:1 to 1:20, preferably 1:2 to 1:20, more preferably 1:5 to 1:20, for example 1:8, 1:10.

[0069] In another preferred embodiment, the shaking treatment time is 0.5-6 h, preferably 1-6 h, such as 4 h.

[0070] In another preferred embodiment, in the step (6), the decellularization treatment includes a step of mixing with a decellularization agent.

[0071] In another preferred embodiment, in the step (6), the decellularization treatment includes mixing with a decellularization agent, and discarding the liquid layer after oscillation treatment.

[0072] In another preferred embodiment, the decellularizing agent is selected from SDS, TritonX-100, sodium deoxycholate, or a combination thereof.

[0073] In another preferred embodiment, the concentration of the decellularizing agent is 0.2-5%, preferably 0.5-2%, more preferably 0.8-1.5%, for example 1%.

[0074] In another preferred embodiment, the mass ratio of the solid content obtained after disinfection to the decellularizing agent is 1:1 to 1:20, preferably 1:2 to 1:20, more preferably 1:5 to 1:20, such as 1:8 or 1:10.

[0075] In another preferred embodiment, the oscillation treatment time is 12-96 hours, such as 12 hours, 24 hours, 48 ​​hours, and 72 hours.

[0076] In another preferred embodiment, in the step (6), the degreasing treatment includes the step of mixing with a degreasing agent.

[0077] In another preferred embodiment, in the step (6), the degreasing treatment includes mixing with a degreasing agent, and discarding the liquid layer after shaking.

[0078] In another preferred embodiment, the degreasing agent is selected from isopropyl alcohol, ethanol, ether, or a combination thereof.

[0079] In another preferred embodiment, the mass ratio of the solid content obtained after decellularization to the degreasing agent is 1:1 to 1:20, preferably 1:2 to 1:20, more preferably 1:5 to 1:20, for example 1:6, 1:8, 1:10.

[0080] In another preferred embodiment, the oscillation treatment time is 0.5-8h, preferably 2-8h, such as 3h, 4h.

[0081] In another preferred embodiment, the emulsification treatment, disinfection treatment, decellularization treatment and defatting treatment optionally further include a post-treatment step of washing.

[0082] In another preferred embodiment, the cleaning includes sequentially cleaning with a PBS solution and cleaning with purified water.

[0083] In another preferred embodiment, the step (7) comprises the following steps:

[0084] (7a) mixing the fat extract D obtained in step (6) with water and stirring to obtain an emulsion;

[0085] (7b) adding the fat extract C to the emulsion obtained in step (a) and mixing;

[0086] (7c) The adipose decellularized biomaterial is obtained after freeze drying.

[0087] In another preferred embodiment, in the step (7a), the mass ratio of the fat extract D to water is 1:5 to 1:50, preferably 1:10 to 1:50, more preferably 1:10 to 1:30, for example 1:20.

[0088] In another preferred embodiment, the step (7c) further includes the steps of first injecting into a mold and then freeze-drying.

[0089] In another preferred embodiment, in the step (7c), the freeze-drying includes the steps of pre-freezing and then freeze-drying.

[0090] In another preferred embodiment, in the step (7c), the freeze-drying comprises the steps of pre-freezing at -50 to -150°C for 12 to 24 hours, and then freeze-drying for 24 to 48 hours.

[0091] In a second aspect of the present invention, a method for preparing the adipose decellularized biomaterial according to the first aspect of the present invention is provided, the method comprising the following steps:

[0092] (1) providing a fat tissue raw material, crushing the fat tissue raw material, and rinsing the fat tissue raw material to obtain rinsed fat tissue;

[0093] (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer;

[0094] (3) emulsifying the intermediate layer to obtain an emulsified fat mixture;

[0095] (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B;

[0096] (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract C;

[0097] (6) sequentially subjecting the primary fat extract B to emulsification, disinfection, decellularization and defatting treatments to obtain acellular fat extract D;

[0098] (7) The cell-free fat extract C is mixed with D, and post-processed to obtain the adipose decellularized biomaterial.

[0099] In another preferred embodiment, the method is as described in the first aspect of the present invention.

[0100] In the third aspect of the present invention, a medical material is provided, comprising: the adipose decellularized biomaterial as described in the first aspect of the present invention, and a pharmaceutically acceptable carrier.

[0101] In the fourth aspect of the present invention, a medical cosmetic material is provided, the medical cosmetic material comprising: the adipose decellularized biomaterial as described in the first aspect of the present invention, and an acceptable carrier in the field of medical cosmetics.

[0102] In a fifth aspect of the present invention, a tissue repair material is provided, wherein the tissue repair material comprises the adipose decellularized biomaterial as described in the first aspect of the present invention.

[0103] In another preferred embodiment, the tissue repair material is an injectable tissue repair material.

[0104] In another preferred embodiment, the tissue repair material further comprises an acceptable carrier.

[0105] In another preferred embodiment, the tissue repair material further comprises a flow agent selected from the following group: physiological saline, PBS buffer, glycerol, polyethylene glycol, or a combination thereof.

[0106] In another preferred embodiment, the tissue repair material is applied to the site requiring tissue repair by injection or direct filling of a surgical opening.

[0107] In the sixth aspect of the present invention, there is provided a use of the adipose decellularized biomaterial as described in the first aspect of the present invention for preparing a medical material or a medical cosmetic material, wherein the medical material is used for soft tissue repair and the medical cosmetic material is used for plastic surgery filling.

[0108] In a seventh aspect of the present invention, a method for soft tissue repair is provided, the method comprising applying the adipose decellularized biomaterial according to the first aspect of the present invention to a subject in need thereof.

[0109] In an eighth aspect of the present invention, a method for plastic surgery and filling is provided, the method comprising applying the adipose decellularized biomaterial as described in the first aspect of the present invention to a subject in need thereof.

[0110] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION

[0111] After extensive and in-depth research, the inventors have discovered for the first time a cell-free adipose decellularized biomaterial rich in a mixture of active adipose proteins. The biomaterial retains the active protein factors of human tissues themselves, and has stronger activity and higher biosafety than recombinant active protein factors; the active proteins are evenly dispersed in the biomaterial, which can achieve sustained release of active proteins in damaged tissue areas, and have a very long-lasting repair effect, thereby accurately promoting angiogenesis in the wound site for a long time; in addition, the freeze-dried biomaterial has a porous structure, which can promote rapid repair of tissues and can be preserved for a long time. The present invention was completed on this basis.

[0112] the term

[0113] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0114] As used herein, the terms "comprise", "include", and "contain" are used interchangeably and include not only closed definitions, but also semi-closed and open definitions. In other words, the terms include "consisting of", "consisting essentially of".

[0115] As used herein, when used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0116] In the present invention, the term "room temperature" refers to 10-40°C.

[0117] Adipose decellularized biomaterials

[0118] As used herein, the terms "fat decellularized biomaterial", "biomaterial of the present invention", etc. are used interchangeably and refer to the fat decellularized biomaterial prepared by mixing the acellular fat extract solution in the fat mixture obtained by washing and crushing the adipose tissue and the acellular fat extract solid obtained by decellularizing and defatting the fat mixture.

[0119] The biomaterial of the present invention includes acellular fat extract without added components (ie, acellular fat extract C, CEFFE) and adipose decellularized matrix (ie, acellular fat extract D).

[0120] The cell-free fat extract refers to an extract (or extracting liquid) obtained by filtering and sterilizing the intermediate cell-free liquid obtained by removing residual oil, adipose tissue, and cell / tissue fragment precipitation after emulsified fat separation. The cell-free fat extract contains a variety of growth factors, such as insulin-like growth factor 1, brain-derived neurotrophic factor, glial cell-derived neurotrophic factor, basic fibroblast growth factor, vascular endothelial growth factor, transforming growth factor-β, hepatocyte growth factor, and platelet-derived growth factor.

[0121] The adipose decellularized matrix refers to the extract obtained by further emulsifying, disinfecting, decellularizing and defatting the cell / tissue fragments precipitated after emulsified fat separation. The adipose decellularized matrix contains macromolecular collagen, glycosaminoglycans, elastin, laminin, fibronectin and other substances, which are good tissue repair materials themselves and can be used as sustained-release carriers of CEFFE.

[0122] The biomaterial of the present invention is a solid block material. The active protein is evenly dispersed in the matrix or carrier of the biomaterial through a process, has an excellent sustained-release effect, and can be injected into the area requiring tissue repair and / or plastic filling, having a long-term repair effect.

[0123] The biomaterial of the present invention is a fat extract without added ingredients, and is an extract derived from adipose tissue prepared without adding any solution, solvent, small molecule, chemical agent, or biological additive during the preparation process (except for the rinsing step).

[0124] A typical method for preparing the biomaterial of the present invention is as described in the second aspect of the present invention. In addition, it should be understood that, although it is not necessary to add any additives (or added ingredients) to the biomaterial of the present invention during the preparation process, some or a small amount of safe substances (such as a small amount of water, PBS buffer, physiological saline, etc.) that have no negative or adverse effects on the activity of the extract of the present invention can also be added.

[0125] Preparation method of adipose decellularized biomaterial

[0126] The present invention provides a method for preparing a fat decellularized biomaterial, comprising the following steps:

[0127] (1) providing a fat tissue raw material, breaking the fat tissue raw material, and rinsing it (e.g., using physiological saline) to obtain rinsed fat tissue;

[0128] (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer;

[0129] (3) emulsifying the intermediate layer to obtain an emulsified fat mixture;

[0130] (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B;

[0131] (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract solution C;

[0132] (6) subjecting the primary fat extract B to emulsification treatment, disinfection treatment, decellularization treatment, and defatting treatment in sequence, thereby obtaining a cell-free fat extract solid D;

[0133] (7) The cell-free fat extract C is mixed with D, and then freeze-dried and sterilized to obtain the final adipose decellularized biomaterial E.

[0134] As the preferred technical solution:

[0135] In another preferred embodiment, in the step (2), the centrifugation is performed at 800-2500 g, preferably 800-2000 g, more preferably 1000-1500 g, and most preferably 1100-1300 g.

[0136] In another preferred embodiment, in the step (2), the centrifugation time is 1-15 min, preferably 1-10 min, more preferably 1-8 min, and most preferably 1-5 min.

[0137] In another preferred embodiment, the centrifugation temperature is 2-6°C.

[0138] In another preferred embodiment, in the step (3), the emulsification is mechanical emulsification.

[0139] In another preferred embodiment, the mechanical emulsification is performed by repeatedly blowing with a syringe (such as blowing 20-200 times, preferably 20-150 times, more preferably 20-100 times, and more preferably 30-50 times).

[0140] In another preferred embodiment, the blowing method is to connect two 10 ml injection syringes to a three-way tube and push and beat repeatedly at a uniform speed.

[0141] In another preferred embodiment, in the step (3), the emulsification is performed by breaking up the tissue using a tissue homogenizer.

[0142] In another preferred embodiment, in the step (4), before subjecting the emulsified fat mixture to centrifugal treatment, the step further includes subjecting the emulsified fat mixture to freezing and then thawing.

[0143] In another preferred embodiment, after the freezing and thawing treatment, the thawed mixture is used for centrifugation.

[0144] In another preferred embodiment, the freezing temperature is -50°C to -120°C, preferably -60°C to -100°C, and more preferably -70°C to -90°C.

[0145] In another preferred embodiment, the thawing temperature is 20-40°C, preferably 25-40°C, and more preferably 37°C.

[0146] In another preferred embodiment, the number of cycles of freezing and thawing is 1-5 times (preferably 1, 2, 3 or 4 times).

[0147] In another preferred embodiment, in the step (4), after centrifugation, the emulsified fat mixture is stratified into four layers, the first layer is an oil layer, the second layer is a residual fat tissue layer, the third layer is a liquid layer (i.e., an intermediate liquid layer), and the fourth layer is a cell / tissue fragment precipitation layer.

[0148] In another preferred embodiment, in the step (4), the centrifugation is performed at 800-2500 g, preferably 800-2000 g, more preferably 1000-1500 g, and most preferably 1100-1300 g.

[0149] In another preferred embodiment, in the step (4), the centrifugation time is 1-15 min, preferably 1-10 min, more preferably 2-8 min, and most preferably 3-7 min.

[0150] In another preferred embodiment, the centrifugation temperature is 2-6°C.

[0151] In another preferred embodiment, in the step (4), the first layer, the second layer, the third layer and the fourth layer are arranged in sequence from top to bottom.

[0152] In another preferred embodiment, in the step (4), the intermediate liquid layer is a transparent or substantially transparent layer, and the intermediate solid layer is yellow or brown.

[0153] In another preferred embodiment, in the step (5), the filtration is capable of removing fat cells from the primary fat extract.

[0154] In another preferred embodiment, in the step (5), the filtration and sterilization are performed through a filter (such as a 0.22 μm microporous filter membrane).

[0155] In another preferred embodiment, the filter is a microporous membrane filter.

[0156] In another preferred embodiment, the pore size of the microporous filter membrane is 0.05-0.8 μm, preferably 0.1-0.5 μm, more preferably 0.1-0.4 μm, more preferably 0.15-0.3 μm, more preferably 0.2-0.25 μm, and most preferably 0.22 μm.

[0157] In another preferred embodiment, in the step (5), the filtration and sterilization are first performed through a first filter that can filter out cells, and then through a second filter (such as a 0.22 μm filter) that can filter out pathogens (such as bacteria).

[0158] In another preferred embodiment, the step (5) further comprises packaging the fat extract to form packaged products. (The packaged extract can be stored at -20°C for use; can be used directly after thawing at low temperature (such as -4°C) or room temperature, or can be stored at low temperature (such as 4°C) for a period of time after thawing before use).

[0159] Furthermore, in step (6), the method of emulsifying the primary fat extract B is preferably to use a homogenizer for mechanical emulsification and centrifugal separation of the oil layer, the emulsification speed is preferably 5000-15000 r / min, the emulsification time is preferably 0.5-5 min, the centrifugal speed is preferably 2000-5000 r / min, and the centrifugal time is preferably 5-15 min.

[0160] Furthermore, the solvent used for disinfection treatment is a peracetic acid / ethanol mixed solution, the concentration of peracetic acid is preferably 0.1-3%, the concentration of ethanol is preferably 4-24%, the mass ratio of the contents to the peracetic acid / ethanol mixed solution is preferably 1:2-1:20, the treatment time is preferably 1-6h, and the liquid layer is discarded after treatment, and PBS solution washing and purified water washing are performed in turn.

[0161] Furthermore, the decellularizing agent is preferably SDS, TritonX-100 and sodium deoxycholate, the decellularizing agent concentration is preferably 0.5-5%, the mass ratio of the content and the decellularizing agent solution is preferably 1:2-1:20, the treatment time is preferably 12h-72h, and the liquid layer is discarded after treatment, and washed with PBS solution and purified water in turn.

[0162] Furthermore, the degreasing agent is preferably isopropanol, ethanol, or ether, the mass ratio of the content to the decellularizing agent solution is preferably 1:2-1:10, the treatment time is preferably 2h-8h, the liquid layer is discarded after treatment, and the cells are washed with PBS solution and purified water in sequence.

[0163] Furthermore, the effect of removing impurities can be adjusted by adjusting the mass ratio of the solid content to the reagents in each step, or the processing time.

[0164] Furthermore, in step (7), the cell-free fat extract C and D are mixed in the following manner:

[0165] (1) adding a certain amount of fat extract D to water and stirring until a uniform emulsion is formed;

[0166] (2) slowly adding fat extract C into the above-mentioned uniform emulsion and mixing;

[0167] (3) The adipose decellularized biomaterial E is obtained after injection molding and freeze drying.

[0168] Further, the freeze-drying process conditions are: pre-freezing for 1-24 hours and freeze drying for 24-72 hours.

[0169] Tissue repair materials

[0170] The adipose decellularized biological material of the present invention is prepared by freeze drying, and the active protein factors in the material can be stored for a long time without losing activity.

[0171] In practical applications, the adipose decellularized biomaterial described in the present invention can be mixed with solutions such as physiological saline, PBS buffer, glycerol, polyethylene glycol, etc. in a certain mass ratio. Mixing with these materials can give the adipose decellularized biomaterial described in the present invention corresponding fluidity so that it can be injected into irregular tissue defect sites, which is convenient for clinical use.

[0172] Therefore, another aspect of the present invention also includes a composition of adipose decellularized biomaterials. The adipose decellularized biomaterial of the present invention can be mixed with a carrier to form an injectable tissue repair material with fluidity.

[0173] Medical materials and administration methods

[0174] Since the biomaterial of the present invention has excellent activity in promoting tissue repair and improving fibrin regeneration, the biomaterial of the present invention and tissue repair materials containing the biomaterial of the present invention as a main active ingredient can be used for soft tissue repair and / or plastic surgery filling.

[0175] The tissue repair material of the present invention comprises the biomaterial of the present invention within a safe and effective amount and a pharmaceutically acceptable excipient or carrier. The "safe and effective amount" means that the amount of the material is sufficient to significantly improve the condition without causing serious side effects. The therapeutically effective amount is determined based on the age, condition, course of treatment, etc. of the subject. Generally, the tissue repair material contains 1-2000 mg of the biomaterial of the present invention / dose, and more preferably, contains 10-1000 mg of the biomaterial of the present invention / dose.

[0176] The "pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the biomaterial of the present invention and with each other without significantly reducing the efficacy of the biomaterial. Examples of pharmaceutically acceptable carriers include sugars (such as glucose, sucrose, lactose, etc.), gelatin, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tween), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0177] The administration method of the biomaterial or medical or medical cosmetic material of the present invention is not particularly limited, and representative administration methods include (but are not limited to): parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

[0178] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0179] The dosage forms of the biomaterial of the present invention for topical administration include gels, ointments, powders, patches, sprays and inhalants. The active ingredient is mixed with a physiologically acceptable carrier and any preservatives and buffers under sterile conditions.

[0180] The biomaterial and the pharmaceutically acceptable salt thereof of the present invention can be administered alone or in combination with other pharmaceutically acceptable therapeutic agents.

[0181] The treatment method of the present invention can be used alone or in combination with other treatment methods or therapeutic drugs.

[0182] When using a pharmaceutical composition, a safe and effective amount of the biomaterial of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage, and for a person weighing 60 kg, the daily dosage is usually 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill range of a skilled physician.

[0183] The main advantages of the present invention include:

[0184] (1) In the process of fat decellularization, the present invention first extracts the fat-rich active protein mixture by an additive-free method to ensure that it is cell-free, sterile, and virus-free, thereby avoiding the removal and contamination of these active protein factors by chemical or biological reagents during the decellularization process. The obtained fat decellularized biomaterial retains a large amount of active protein factors compared to the known process.

[0185] (2) The adipose decellularized biomaterial of the present invention retains the active protein factors of human tissue itself, and has stronger activity and higher biosafety than recombinant active protein factors.

[0186] (3) The active protein in the adipose decellularized biomaterial of the present invention is evenly dispersed in the biomaterial through a process and adheres to the collagen fibers in the biomaterial. During use, the active protein can be sustained-released in the damaged tissue area (can remain effective for 3 to 6 months), and can accurately promote angiogenesis in the wound site for a long time, thereby achieving the goal of repairing tissue function.

[0187] (4) The freeze-dried adipose decellularized biomaterial has a porous structure, can be preserved for a long time, and is easy to realize industrial production.

[0188] (5) The adipose decellularized biomaterial of the present invention does not introduce exogenous proteins or materials and has good biocompatibility with human tissues.

[0189] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for the unrecorded specific conditions in the following examples are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.

[0190] Embodiment 1:

[0191] The present invention prepares a fat decellularized biomaterial according to the following method, which comprises the steps of preparing a fat primary extract A and a fat primary extract B, and the step of preparing the fat decellularized biomaterial.

[0192] a. Preparation of primary fat extract A and primary fat extract B

[0193] (a1) Adipose tissue was obtained from 6 healthy women who underwent conventional liposuction, with an average age of 31 years (range, 24-36 years). After local injection of tumescent fluid for anesthesia, a 3 mm liposuction cannula with a large side hole (2 mm × 7 mm) was connected to a 20 mL syringe and radial suction was performed under artificial negative pressure. The obtained fat was placed upright and still, and after removing the tumescent fluid, it was rinsed three times with saline.

[0194] (a2) The washed adipose tissue was placed in a centrifuge tube, and centrifuged at 1200 g at 4° C. for 3 minutes to obtain a layered mixture.

[0195] (a3) For the stratified mixture, the upper oil layer and the lower water layer are removed, and the middle layer (i.e., the fat layer containing fat cells) is collected.

[0196] (a4) The intermediate layer is mechanically emulsified by repeatedly pushing and beating at a constant speed 30 times using two 10 ml syringes connected to a three-way tube to obtain a mechanically emulsified fat mixture (also called nano fat).

[0197] (a5) The mechanically emulsified fat mixture is placed in a -80°C freezer for freezing, and then thawed in a 37°C water bath. After a single freeze-thaw cycle, the thawed fat mixture is centrifuged at 1200g and 4°C for 5 minutes to obtain a layered mixture. The layered mixture is divided into 4 layers, the first layer is an oil layer, the second layer is a residual fat tissue layer, the third layer is a liquid layer, and the fourth layer is a cell / tissue fragment precipitation layer.

[0198] (a6) removing the oil layer and the cell / tissue debris sedimentation layer, taking the liquid layer, i.e., the primary fat extract A, and taking the residual adipose tissue layer (solid layer), i.e., the primary fat extract B.

[0199] (a7) The obtained primary fat extract A is sterilized by filtration through a 0.22 μm filter to sterilize and remove any living cells that may be mixed, thereby obtaining a cell-free fat extract C (CEFFE), which is then divided into aliquots and frozen at -20°C and thawed at 4°C before use.

[0200] b. Preparation of adipose decellularized biomaterials

[0201] (b1) The primary fat extract B was emulsified at 10,000 r / min for 2 minutes using a homogenizer, and centrifuged at 4,000 r / min for 10 minutes to separate the oil layer and obtain the solid content.

[0202] (b2) adding the solid contents obtained in step (b1) into a 0.5% / 4% peracetic acid / ethanol disinfectant at a mass ratio of 1:10 and shaking for 4 hours, discarding the liquid layer after treatment, and washing the solid contents with PBS solution and purified water in turn by shaking to obtain solid contents.

[0203] (b3) adding the solid contents obtained in step (b2) into 1% TritonX-100 at a mass ratio of 1:10 and shaking for 72 hours, changing the solution once every 8 hours, discarding the liquid layer after treatment, and washing the solid contents with PBS solution and purified water in turn by shaking to obtain solid contents.

[0204] (b4) adding the solid content obtained in step (b3) into ether at a mass ratio of 1:6 and shaking for 3 hours, discarding the liquid layer after treatment, and washing with PBS solution and purified water in sequence to obtain solid content.

[0205] (b5) adding the solid content obtained in step (b4) to 20 times the mass of purified water, stirring evenly to form a uniform emulsion (acellular fat extract D), and slowly adding the fat extract C solution to the above uniform emulsion and mixing well. Injecting into a mold, pre-freezing at -80 degrees for 12 hours, freeze-drying for 48 hours, and obtaining adipose acellular biomaterial.

[0206] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A fat decellularized biomaterial, characterized in that: The adipose decellularized biomaterial is prepared by the following method, which comprises the following steps: (1) providing a fat tissue raw material, crushing the fat tissue raw material, and rinsing the fat tissue raw material to obtain rinsed fat tissue; (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer; (3) emulsifying the intermediate layer to obtain an emulsified fat mixture; (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B; (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract C; (6) sequentially subjecting the primary fat extract B to emulsification, disinfection, decellularization and defatting treatments to obtain acellular fat extract D; (7) The cell-free fat extract C is mixed with D, and post-processed to obtain the adipose decellularized biomaterial.

2. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (4), after centrifugation, the emulsified fat mixture is divided into four layers, the first layer is an oil layer, the second layer is a residual fat tissue layer (i.e., an intermediate solid layer), the third layer is a liquid layer (i.e., an intermediate liquid layer), and the fourth layer is a cell / tissue fragment precipitation layer.

3. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (6), the emulsification treatment includes homogenizing and emulsifying with a homogenizer, the emulsification treatment also includes a step of centrifugally separating the oil layer, and the emulsification treatment includes one or more features selected from the following group: (1) The rotation speed of the homogenizer is 5000-15000 r / min; (2) The emulsification time is 0.5-15 min; (3) the centrifugation is performed at 1000-8000 r / min; (4) The centrifugation time is 2-20 min.

4. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (6), the disinfection treatment includes mixing with a disinfectant, and discarding the liquid layer after oscillation treatment; and the disinfection treatment also includes one or more features selected from the following group: (1) The disinfectant is a mixed solution of peracetic acid and ethanol, the concentration of the peracetic acid is 0.05-3%, and the concentration of the ethanol is 1-24%; (2) The mass ratio of the solid content obtained after emulsification to the disinfectant is 1:1 to 1:20; (3) The shaking treatment time is 0.5-6h.

5. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (6), the decellularization treatment includes mixing with a decellularization agent, and discarding the liquid layer after oscillation treatment; and the decellularization treatment also includes one or more features selected from the following group: (1) The decellularizing agent is selected from SDS, TritonX-100, sodium deoxycholate, or a combination thereof; (2) the concentration of the decellularizing agent is 0.2-5%; (3) The mass ratio of the solid content obtained after disinfection to the decellularizing agent is 1:1 to 1:20; (4) The shaking treatment time is 12-96 hours.

6. The adipose decellularized biomaterial according to claim 1, characterized in that: In the step (6), the degreasing treatment includes mixing with a degreasing agent, and discarding the liquid layer after oscillation treatment; and the degreasing treatment also includes one or more characteristics selected from the following group: (1) The degreasing agent is selected from isopropyl alcohol, ethanol, ether, or a combination thereof. (2) the mass ratio of the solid content obtained after decellularization to the degreasing agent is 1:1 to 1:20; (3) The shaking treatment time is 0.5-8h.

7. The adipose decellularized biomaterial according to claim 1, characterized in that: The step (7) comprises the following steps: (7a) mixing the fat extract D obtained in step (6) with water and stirring to obtain an emulsion; (7b) adding the fat extract C to the emulsion obtained in step (a) and mixing; (7c) The adipose decellularized biomaterial is obtained after freeze drying.

8. A method for preparing adipose decellularized biomaterial according to claim 1, characterized in that: The method comprises the following steps: (1) providing a fat tissue raw material, crushing the fat tissue raw material, and rinsing the fat tissue raw material to obtain rinsed fat tissue; (2) centrifuging the rinsed adipose tissue to obtain a layered mixture, removing the upper oil layer and the lower water layer, and collecting the middle layer; (3) emulsifying the intermediate layer to obtain an emulsified fat mixture; (4) centrifuging the emulsified fat mixture to obtain an intermediate liquid layer, namely, the primary fat extract A; and obtaining an intermediate solid layer, namely, the primary fat extract B; (5) filtering and sterilizing the primary fat extract A to obtain a cell-free fat extract C; (6) sequentially subjecting the primary fat extract B to emulsification, disinfection, decellularization and defatting treatments to obtain acellular fat extract D; (7) The cell-free fat extract C is mixed with D, and post-processed to obtain the adipose decellularized biomaterial.

9. A tissue repair material, characterized in that: The tissue repair material comprises the adipose decellularized biomaterial as claimed in claim 1.

10. The use of the adipose decellularized biomaterial according to claim 1, characterized in that: Used to prepare a medical material or a medical cosmetic material, wherein the medical material is used for soft tissue repair and the medical cosmetic material is used for plastic surgery filling.